Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023)

Neurocrine Biosciences (NBIX) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $100000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to $100000.0, compared with a TTM value of $700000.0 through Dec 2023, changed N/A, and an annual FY2023 reading of $700000.0, down 41.67% over the prior year.
  • Amortization of Deferred Charges was $100000.0 for Q4 2023 at Neurocrine Biosciences, down from $200000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $400000.0 in Q2 2020 and bottomed at $100000.0 in Q4 2023.
  • Average Amortization of Deferred Charges over 4 years is $270000.0, with a median of $300000.0 recorded in 2019.
  • The sharpest move saw Amortization of Deferred Charges decreased 7.98% in 2019, then changed 0.0% in 2020.
  • Year by year, Amortization of Deferred Charges stood at $300000.0 in 2019, then soared by 33.33% to $400000.0 in 2020, then fell by 25.0% to $300000.0 in 2021, then crashed by 66.67% to $100000.0 in 2023.
  • Business Quant data shows Amortization of Deferred Charges for NBIX at $100000.0 in Q4 2023, $200000.0 in Q3 2023, and $200000.0 in Q2 2023.